|
1
|
Safaei M, Sundararajan EA, Driss M,
Boulila W and Shapi'i A: A systematic literature review on obesity:
Understanding the causes & consequences of obesity and
reviewing various machine learning approaches used to predict
obesity. Comput Biol Med. 136(104754)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Konttinen H: Emotional eating and obesity
in adults: The role of depression, sleep and genes. Proc Nutr Soc.
79:283–289. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tappia PS and Defries D: Prevalence,
consequences, causes and management of obesity. In: Pathophysiology
of Obesity-Induced Health Complications. Springer, Heidelberg,
pp3-22, 2020.
|
|
4
|
Omer T: The causes of obesity: An in-depth
review. Adv Obes Weight Manag Control. 10:90–94. 2020.
|
|
5
|
Franco M, Orduñez P, Caballero B, Tapia
Granados JA, Lazo M, Bernal JL, Guallar E and Cooper RS: Impact of
energy intake, physical activity, and population-wide weight loss
on cardiovascular disease and diabetes mortality in Cuba,
1980-2005. Am J Epidemiol. 166:1374–1380. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Popoviciu MS, Păduraru L, Yahya G,
Metwally K and Cavalu S: Emerging role of GLP-1 agonists in
obesity: A comprehensive review of randomised controlled trials.
Int J Mol Sci. 24(10449)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lebovitz HE and Banerji MA: Point:
Visceral adiposity is causally related to insulin resistance.
Diabetes Care. 28:2322–2325. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Crowley N, Arlinghaus KR and Myers ES:
Dietary management of overweight and obesity. In: Lifestyle
Medicine. 3rd edition. CRC Press, pp483-489, 2019.
|
|
9
|
Hotamisligil GS: Inflammation and
metabolic disorders. Nature. 444:860–867. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Maurizi G, Della Guardia L, Maurizi A and
Poloni A: Adipocytes properties and crosstalk with immune system in
obesity-related inflammation. J Cell Physiol. 233:88–97.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Herman MA, Peroni OD, Villoria J, Schön
MR, Abumrad NA, Blüher M, Klein S and Kahn BB: A novel ChREBP
isoform in adipose tissue regulates systemic glucose metabolism.
Nature. 484:333–338. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grundy SM: Metabolic complications of
obesity. Endocrine. 13:155–165. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mahapatra MK, Karuppasamy M and Sahoo BM:
Semaglutide, a glucagon like peptide-1 receptor agonist with
cardiovascular benefits for management of type 2 diabetes. Rev
Endocr Metab Disord. 23:521–539. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lutter M and Nestler EJ: Homeostatic and
hedonic signals interact in the regulation of food intake. J Nutr.
139:629–632. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ferrario CR, Labouèbe G, Liu S, Nieh EH,
Routh VH, Xu S and O'Connor EC: Homeostasis meets motivation in the
battle to control food intake. J Neurosci. 36:11469–11481.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Welle S and Campbell RG: Stimulation of
thermogenesis by carbohydrate overfeeding. Evidence against
sympathetic nervous system mediation. J Clin Invest. 71:916–925.
1983.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Young JB and Landsberg L: Suppression of
sympathetic nervous system during fasting. Obes Res. 5:646–649.
1997.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hesse S, van de Giessen E, Zientek F,
Petroff D, Winter K, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum
S, Darcourt J, et al: Association of central serotonin transporter
availability and body mass index in healthy Europeans. Eur
Neuropsychopharmacol. 24:1240–1247. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Blum K, Thanos PK and Gold MS: Dopamine
and glucose, obesity, and reward deficiency syndrome. Front
Psychol. 5(919)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
English PJ, Ghatei MA, Malik IA, Bloom SR
and Wilding JPH: Food fails to suppress ghrelin levels in obese
humans. J Clin Endocrinol Metab. 87(2984)2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
El-Haschimi K, Pierroz DD, Hileman SM,
Bjørbæk C and Flier JS: Two defects contribute to hypothalamic
leptin resistance in mice with diet-induced obesity. J Clin Invest.
105:1827–1832. 2000.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Apovian CM, Aronne LJ, Bessesen DH,
McDonnell ME, Murad MH, Pagotto U, Ryan DH and Still CD: Endocrine
Society. Pharmacological management of obesity: An endocrine
society clinical practice guideline. J Clin Endocrinol Metab.
100:342–362. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Obesity WHOJIAftSo, International Obesity
Task Force TA-Ppro and treatment i: Regional Office for the Western
Pacific, 2000.
|
|
24
|
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ,
Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, et
al: Clinical characteristics of Covid-19 in New York city. N Engl J
Med. 382:2372–2374. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nakeshbandi M, Maini R, Daniel P,
Rosengarten S, Parmar P, Wilson C, Kim JM, Oommen A, Mecklenburg M,
Salvani J, et al: The impact of obesity on COVID-19 complications:
A retrospective cohort study. Int J Obes (Lond). 44:1832–1837.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Haupt TH, Kallemose T, Ladelund S,
Rasmussen LJ, Thorball CW, Andersen O, Pisinger C and Eugen-Olsen
J: Risk factors associated with serum levels of the inflammatory
biomarker soluble urokinase plasminogen activator receptor in a
general population. Biomark Insights. 9:91–100. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Frasca D, Reidy L, Cray C, Diaz A, Romero
M, Kahl K and Blomberg BB: Influence of obesity on serum levels of
SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS One.
16(e0245424)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bell GI, Sanchez-Pescador R, Laybourn PJ
and Najarian RCJN: Exon duplication and divergence in the human
preproglucagon gene. Nature. 304:368–371. 1983.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gutniak M, Orskov C, Holst JJ, Ahrén B and
Efendic S: Antidiabetogenic effect of glucagon-like peptide-1
(7-36) amide in normal subjects and patients with diabetes
mellitus. N Engl J Med. 326:1316–1322. 1992.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Drucker DJ, Buse JB, Taylor K, Kendall DM,
Trautmann M, Zhuang D and Porter L: DURATION-1 Study Group.
Exenatide once weekly versus twice daily for the treatment of type
2 diabetes: A randomised, open-label, non-inferiority study.
Lancet. 372:1240–1250. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Coskun T, Sloop KW, Loghin C,
Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera
O, Roell WC, et al: LY3298176, a novel dual GIP and GLP-1 receptor
agonist for the treatment of type 2 diabetes mellitus: From
discovery to clinical proof of concept. Mol Metab. 18:3–14.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nauck MA, Heimesaat MM, Orskov C, Holst
JJ, Ebert R and Creutzfeldt W: Preserved incretin activity of
glucagon-like peptide 1 [7-36 amide] but not of synthetic human
gastric inhibitory polypeptide in patients with type-2 diabetes
mellitus. J Clin Invest. 91:301–307. 1993.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Holst JJ: Glucagon-like peptide-1: Are its
roles as endogenous hormone and therapeutic wizard congruent? J
Intern Med. 291:557–573. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kim HS and Jung CH: Oral semaglutide, the
first ingestible glucagon-like peptide-1 receptor agonist: Could it
be a magic bullet for type 2 diabetes? Int J Mol Sci.
22(9936)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Saxena AR, Gorman DN, Esquejo RM, Bergman
A, Chidsey K, Buckeridge C, Griffith DA and Kim AM: Danuglipron
(PF-06882961) in type 2 diabetes: A randomized, placebo-controlled,
multiple ascending-dose phase 1 trial. Nat Med. 27:1079–1087.
2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xia L, Shen T, Dong W, Su F, Wang J, Wang
Q, Niu S and Fang Y: Comparative efficacy and safety of 8 GLP-1RAs
in patients with type 2 diabetes: A network meta-analysis. Diabetes
Res Clin Pract. 177(108904)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gabery S, Salinas CG, Paulsen SJ,
Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E,
Fekete C, Frederiksen KS, et al: Semaglutide lowers body weight in
rodents via distributed neural pathways. JCI Insight.
5(e133429)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Secher A, Jelsing J, Baquero AF,
Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL,
Pyke C, Raun K, et al: The arcuate nucleus mediates GLP-1 receptor
agonist liraglutide-dependent weight loss. J Clin Invest.
124:4473–4488. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Brandt SJ, Müller TD, DiMarchi RD, Tschöp
MH and Stemmer K: Peptide-based multi-agonists: A new paradigm in
metabolic pharmacology. J Intern Med. 284:581–602. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wadden TA, Tronieri JS, Sugimoto D, Lund
MT, Auerbach P, Jensen C and Rubino D: Liraglutide 3.0 mg and
intensive behavioral therapy (IBT) for obesity in primary care: The
SCALE IBT randomized controlled trial. Obesity (Silver Spring).
28:529–536. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Müller TD, Blüher M, Tschöp MH and
DiMarchi RD: Anti-obesity drug discovery: Advances and challenges.
Nat Rev Drug Discov. 21:201–223. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lin CH, Shao L, Zhang YM, Tu YJ, Zhang Y,
Tomlinson B, Chan P and Liu Z: An evaluation of liraglutide
including its efficacy and safety for the treatment of obesity.
Expert Opin Pharmacother. 21:275–285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kela R, Khunti K and Davies MJ:
Liraglutide for type 2 diabetes mellitus. Expert Opin Biol Ther.
11:951–959. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gallwitz B: Glucagon-like peptide-1
analogues for Type 2 diabetes mellitus: Current and emerging
agents. Drugs. 71:1675–1688. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Le Roux CW, Astrup A, Fujioka K, Greenway
F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning
LS, et al: 3 Years of liraglutide versus placebo for type 2
diabetes risk reduction and weight management in individuals with
prediabetes: A randomised, double-blind trial. Lancet.
389:1399–1409. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pi-Sunyer X, Astrup A, Fujioka K, Greenway
F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R,
Jensen CB, et al: A randomized, controlled trial of 3.0 mg of
liraglutide in weight management. N Engl J Med. 373:11–22.
2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Grill HJ: A role for GLP-1 in treating
hyperphagia and obesity. Endocrinology. 161(bqaa093)2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hall S, Isaacs D and Clements JN:
Pharmacokinetics and clinical implications of semaglutide: A new
glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet.
57:1529–1538. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Christou GA, Katsiki N, Blundell J,
Fruhbeck G and Kiortsis DN: Semaglutide as a promising antiobesity
drug. Obes Rev. 20:805–815. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Wilding JPH, Batterham RL, Calanna S,
Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran
MTD, Wadden TA, et al: Once-weekly semaglutide in adults with
overweight or obesity. N Engl J Med. 384:989–1002. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Knudsen LB and Lau J: The discovery and
development of liraglutide and semaglutide. Front Endocrinol
(Lausanne). 10(155)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
ElSayed NA, Aleppo G, Aroda VR, Bannuru
RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D,
Johnson EL, et al: 9. Pharmacologic approaches to glycemic
treatment: Standards of care in diabetes-2023. Diabetes Care. 46
(Suppl 1):S140–S157. 2023.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lau J, Bloch P, Schäffer L, Pettersson I,
Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard
DB, et al: Discovery of the once-weekly glucagon-like peptide-1
(GLP-1) analogue semaglutide. J Med Chem. 58:7370–7380.
2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Buckley ST, Bækdal TA, Vegge A, Maarbjerg
SJ, Pyke C, Ahnfelt-Rønne J, Madsen KG, Schéele SG, Alanentalo T,
Kirk RK, et al: Transcellular stomach absorption of a derivatized
glucagon-like peptide-1 receptor agonist. Sci Transl Med.
10(eaar7047)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Aroda VR, Rosenstock J, Terauchi Y,
Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK,
Christiansen E, Hertz CL and Haluzík M: PIONEER 1 Investigators.
PIONEER 1: Randomized clinical trial of the efficacy and safety of
oral semaglutide monotherapy in comparison with placebo in patients
with type 2 diabetes. Diabetes Care. 42:1724–1732. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wharton S, Blevins T, Connery L,
Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, et
al: Daily oral GLP-1 receptor agonist orforglipron for adults with
obesity. N Engl J Med. 389:877–888. 2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Davies M, Pieber TR, Hartoft-Nielsen ML,
Hansen OK, Jabbour S and Rosenstock J: Effect of oral semaglutide
compared with placebo and subcutaneous semaglutide on glycemic
control in patients with type 2 diabetes: A randomized clinical
trial. JAMA. 318:1460–1470. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Reusch JE, Rosenstock J, Bush MA, Yang F
and Stewart MW: Albiglutide, a long-acting GLP-1 receptor agonist,
improves glycemia in type 2 diabetes: Time-course analysis. In:
American Diabetes Association, pA123, 2009.
|
|
59
|
Ørskov C, Poulsen SS, Mørten M and Holst
JJ: Glucagon-like peptide I receptors in the subfornical organ and
the area postrema are accessible to circulating glucagon-like
peptide I. Diabetes. 45:832–835. 1996.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Rosenstock J, Reusch J, Bush M, Yang F and
Stewart M: Albiglutide Study Group. Potential of albiglutide, a
long-acting GLP-1 receptor agonist, in type 2 diabetes: A
randomized controlled trial exploring weekly, biweekly, and monthly
dosing. Diabetes Care. 32:1880–1886. 2009.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Glaesner W, Vick AM, Millican R, Ellis B,
Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, et
al: Engineering and characterization of the long-acting
glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Diabetes Metab Res Rev. 26:287–296. 2010.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Zhang Q, Delessa CT, Augustin R, Bakhti M,
Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger
A, et al: The glucose-dependent insulinotropic polypeptide (GIP)
regulates body weight and food intake via CNS-GIPR signaling. Cell
Metab. 33:833–844.e5. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Barrington P, Chien JY, Tibaldi F,
Showalter HD, Schneck K and Ellis B: LY2189265, a long-acting
glucagon-like peptide-1 analogue, showed a dose-dependent effect on
insulin secretion in healthy subjects. Diabetes Obes Metab.
13:434–438. 2011.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Umpierrez G, Blevins T, Rosenstock J,
Cheng C, Anderson JH and Bastyr EJ III: EGO Study Group. The
effects of LY2189265, a long-acting glucagon-like peptide-1
analogue, in a randomized, placebo-controlled, double-blind study
of overweight/obese patients with type 2 diabetes: The EGO study.
Diabetes Obes Metab. 13:418–425. 2011.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Hollander P, Maggs DG, Ruggles JA, Fineman
M, Shen L, Kolterman OG and Weyer C: Effect of pramlintide on
weight in overweight and obese insulin-treated type 2 diabetes
patients. Obes Res. 12:661–668. 2004.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Enebo LB, Berthelsen KK, Kankam M, Lund
MT, Rubino DM, Satylganova A and Lau DCW: Safety, tolerability,
pharmacokinetics, and pharmacodynamics of concomitant
administration of multiple doses of cagrilintide with semaglutide
2·4 mg for weight management: A randomised, controlled, phase 1b
trial. Lancet. 397:1736–1748. 2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Boyle CN, Lutz TA and Le Foll C:
Amylin-its role in the homeostatic and hedonic control of eating
and recent developments of amylin analogs to treat obesity. Mol
Metab. 8:203–210. 2018.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ling W, Huang YM, Qiao YC, Zhang XX and
Zhao HL: Human amylin: From pathology to physiology and
pharmacology. Curr Protein Pept Sci. 20:944–957. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Day C: Amylin analogue as an antidiabetic
agent. Br J Diabetes Vasc Dis. 5:151–154. 2005.
|
|
70
|
Ravussin E, Smith SR, Mitchell JA,
Shringarpure R, Shan K, Maier H, Koda JE and Weyer C: Enhanced
weight loss with pramlintide/metreleptin: An integrated
neurohormonal approach to obesity pharmacotherapy. Obesity (Silver
Spring). 17:1736–1743. 2009.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Kruse T, Hansen JL, Dahl K, Schäffer L,
Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB,
Dornonville de la Cour C, et al: Development of cagrilintide, a
long-acting amylin analogue. J Med Chem. 64:11183–11194.
2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Lau DCW, Erichsen L, Francisco AM,
Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH,
Rubino D and Batterham RL: Once-weekly cagrilintide for weight
management in people with overweight and obesity: A multicentre,
randomised, double-blind, placebo-controlled and active-controlled,
dose-finding phase 2 trial. Lancet. 398:2160–2172. 2021.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Sidrak WR, Kalra S and Kalhan A: Approved
and emerging hormone-based anti-obesity medications: A review
article. Indian J Endocrinol Metab. 28:445–460. 2024.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kaneko K, Fu Y, Lin HY, Cordonier EL, Mo
Q, Gao Y, Yao T, Naylor J, Howard V, Saito K, et al: Gut-derived
GIP activates central Rap1 to impair neural leptin sensitivity
during overnutrition. J Clin Invest. 129:3786–3791. 2019.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Mroz PA, Finan B, Gelfanov V, Yang B,
Tschöp MH, DiMarchi RD and Perez-Tilve D: Optimized GIP analogs
promote body weight lowering in mice through GIPR agonism not
antagonism. Mol Metab. 20:51–62. 2019.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Adriaenssens AE, Biggs EK, Darwish T,
Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova
I, Pan W, et al: Glucose-dependent insulinotropic polypeptide
receptor-expressing cells in the hypothalamus regulate food intake.
Cell Metab. 30:987–996.e6. 2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Borner T, Workinger JL, Tinsley IC, Fortin
SM, Stein LM, Chepurny OG, Holz GG, Wierzba AJ, Gryko D, Nexø E, et
al: Corrination of a GLP-1 receptor agonist for glycemic control
without emesis. Cell Rep. 31(107768)2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Samms RJ, Coghlan MP and Sloop KW: How may
GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol
Metab. 31:410–421. 2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Holst JJ and Rosenkilde MM: GIP as a
therapeutic target in diabetes and obesity: Insight from incretin
co-agonists. J Clin Endocrinol Metab. 105:e2710–e2716.
2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Rosenstock J, Wysham C, Frías JP, Kaneko
S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA and Thieu
VT: Efficacy and safety of a novel dual GIP and GLP-1 receptor
agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A
double-blind, randomised, phase 3 trial. Lancet. 398:143–155.
2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Taylor R, Beveridge D and Fuller PJ:
Expression of ileal glucagon and peptide tyrosine-tyrosine genes.
Response to inhibition of polyamine synthesis in the presence of
massive small-bowel resection. Biochem J. 286:737–741.
1992.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Anini Y, Fu-Cheng X, Cuber JC, Kervran A,
Chariot J and Roz C: Comparison of the postprandial release of
peptide YY and proglucagon-derived peptides in the rat. Pflugers
Arch. 438:299–306. 1999.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Schjoldager BT, Baldissera FG, Mortensen
PE, Holst JJ and Christiansen J: Oxyntomodulin: A potential hormone
from the distal gut. Pharmacokinetics and effects on gastric acid
and insulin secretion in man. Eur J Clin Invest. 18:499–503.
1988.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Hoentjen F, Hopman WP and Jansen JB:
Effect of circulating peptide YY on gallbladder emptying in humans.
Scand J Gastroenterol. 36:1086–1091. 2001.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Tang-Christensen M, Vrang N and Larsen PJ:
Glucagon-like peptide containing pathways in the regulation of
feeding behaviour. Int J Obes Relat Metab Disord. 25 (Suppl
5):S42–S47. 2001.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Holst JJ: Glucagon-like peptide 1 (GLP-1):
An intestinal hormone, signalling nutritional abundance, with an
unusual therapeutic potential. Trends Endocrinol Metab. 10:229–235.
1999.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Baldissera FG and Holst JJ:
Glucagon-related peptides in the human gastrointestinal mucosa.
Diabetologia. 26:223–228. 1984.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Glover I, Haneef I, Pitts J, Wood S, Moss
D, Tickle I and Blundell T: Conformational flexibility in a small
globular hormone: X-ray analysis of avian pancreatic polypeptide at
0.98-A resolution. Biopolymers. 22:293–304. 1983.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Adrian TE, Ferri GL, Bacarese-Hamilton AJ,
Fuessl HS, Polak JM and Bloom SR: Human distribution and release of
a putative new gut hormone, peptide YY. Gastroenterology.
89:1070–1077. 1985.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Ekblad E and Sundler F: Distribution of
pancreatic polypeptide and peptide YY. Peptides. 23:251–261.
2002.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Christoffersen BØ, Sanchez-Delgado G, John
LM, Ryan DH, Raun K and Ravussin E: Beyond appetite regulation:
Targeting energy expenditure, fat oxidation, and lean mass
preservation for sustainable weight loss. Obesity (Silver Spring).
30:841–857. 2022.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Finan B, Yang B, Ottaway N, Smiley DL, Ma
T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, et
al: A rationally designed monomeric peptide triagonist corrects
obesity and diabetes in rodents. Nat Med. 21:27–36. 2015.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Sass F, Ma T, Ekberg JH, Kirigiti M, Ureña
MG, Dollet L, Brown JM, Basse AL, Yacawych WT, Burm HB, et al: NK2R
control of energy expenditure and feeding to treat metabolic
diseases. Nature. 635:987–1000. 2024.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Speakman JR, de Jong JMA, Sinha S,
Westerterp KR, Yamada Y, Sagayama H, Ainslie PN, Anderson LJ, Arab
L, Bedu-Addo K, et al: Total daily energy expenditure has declined
over the past three decades due to declining basal expenditure, not
reduced activity expenditure. Nat Metab. 5:579–588. 2023.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Hauser AS, Attwood MM, Rask-Andersen M,
Schiöth HB and Gloriam DE: Trends in GPCR drug discovery: New
agents, targets and indications. Nat Rev Drug Discov. 16:829–842.
2017.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Brown JC, Mutt V and Pederson RA: Further
purification of a polypeptide demonstrating enterogastrone
activity. J Physiol. 209:57–64. 1970.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Buse JB, Rosenstock J, Sesti G, Schmidt
WE, Montanya E, Brett JH, Zychma M and Blonde L: LEAD-6 Study
Group. Liraglutide once a day versus exenatide twice a day for type
2 diabetes: A 26-week randomised, parallel-group, multinational,
open-label trial (LEAD-6). Lancet. 374:39–47. 2009.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Meier JJ: GLP-1 receptor agonists for
individualized treatment of type 2 diabetes mellitus. Nat Rev
Endocrinol. 8:728–742. 2012.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Astrup A, Rössner S, Van Gaal L, Rissanen
A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF and Lean ME:
NN8022-1807 Study Group. Effects of liraglutide in the treatment of
obesity: A randomised, double-blind, placebo-controlled study.
Lancet. 374:1606–1616. 2009.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Jastreboff AM, Aronne LJ and Stefanski A:
Tirzepatide once weekly for the treatment of obesity. Reply. N Engl
J Med. 387:1434–1435. 2022.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Frías JP, Davies MJ, Rosenstock J, Pérez
Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X and Brown K:
SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly
in patients with type 2 diabetes. N Engl J Med. 385:503–515.
2021.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Garvey WT, Batterham RL, Bhatta M, Buscemi
S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden
TA, et al: Two-year effects of semaglutide in adults with
overweight or obesity: The STEP 5 trial. Nat Med. 28:2083–2091.
2022.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Chao AM, Tronieri JS, Amaro A and Wadden
TA: Clinical insight on semaglutide for chronic weight management
in adults: Patient selection and special considerations. Drug Des
Devel Ther. 16:4449–4461. 2022.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Davies MJ, D'Alessio DA, Fradkin J, Kernan
WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ and Buse
JB: Management of hyperglycemia in type 2 diabetes, 2018. A
consensus report by the American diabetes association (ADA) and the
European association for the study of diabetes (EASD). Diabetes
Care. 41:2669–2701. 2018.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Torbahn G, Lischka J, Brown T, Ells LJ,
Kelly AS, Wabitsch M and Weghuber D: Anti-obesity medication in the
management of children and adolescents with obesity: Recent
developments and research gaps. Clin Endocrinol (Oxf). 102:51–61.
2025.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Torbahn G, Jones A, Griffiths A, Matu J,
Metzendorf MI, Ells LJ, Gartlehner G, Kelly AS, Weghuber D and
Brown T: Pharmacological interventions for the management of
children and adolescents living with obesity-An update of a
Cochrane systematic review with meta-analyses. Pediatr Obes.
19(e13113)2024.PubMed/NCBI View Article : Google Scholar
|
|
107
|
van Boxel EJ, Rahman S, Lai K, Boulos N
and Davis N: Semaglutide treatment for children with obesity: An
observational study. Arch Dis Child. 109:822–825. 2024.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Nedunchezhiyan U, Varughese I, Sun AR, Wu
X, Crawford R and Prasadam I: Obesity, inflammation, and immune
system in osteoarthritis. Front Immunol. 13(907750)2022.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Jensen MD, Ryan DH, Apovian CM, Ard JD,
Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF,
et al: 2013 AHA/ACC/TOS guideline for the management of overweight
and obesity in adults: A report of the American college of
cardiology/American heart association task force on practice
guidelines and the obesity society. Circulation. 129 (Suppl
2):S102–S138. 2014.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Ryan DH and Yockey SR: Weight loss and
improvement in comorbidity: Differences at 5, 10, 15%, and over.
Curr Obes Rep. 6:187–194. 2017.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Roseti L, Desando G, Cavallo C, Petretta M
and Grigolo B: Articular cartilage regeneration in osteoarthritis.
Cells. 8(1305)2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Moiz A, Filion KB, Tsoukas MA, Yu OH,
Peters TM and Eisenberg MJ: Mechanisms of GLP-1 receptor
agonist-induced weight loss: A review of central and peripheral
pathways in appetite and energy regulation. Am J Med: Jan 31, 2025
(Epub ahead of print).
|
|
113
|
Petrongolo G: Liraglutide and
cardiovascular outcomes in diabetes (LEADER)-2016. In: Top Articles
in Primary Care. Russell J and Skolnik NS (eds). Springer
International Publishing, Cham, pp91-94, 2023.
|
|
114
|
Bhagavathula AS, Vidyasagar K and Tesfaye
W: Efficacy and safety of tirzepatide in patients with type 2
diabetes mellitus: A systematic review and meta-analysis of
randomized phase II/III trials. Pharmaceuticals (Basel).
14(991)2021.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Davies MJ, Bergenstal R, Bode B, Kushner
RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB and DeFronzo RA:
NN8022-1922 Study Group. Efficacy of liraglutide for weight loss
among patients with type 2 diabetes: The SCALE diabetes randomized
clinical trial. JAMA. 314:687–699. 2015.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Westermeier F and Fisman EZ: Correction:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and
cardiometabolic protection: Historical development and future
challenges. Cardiovasc Diabetol. 24(118)2025.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Cefalu WT, Kaul S, Gerstein HC, Holman RR,
Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, et
al: Cardiovascular outcomes trials in type 2 diabetes: Where do we
go from here? Reflections from a diabetes care editors' expert
forum. Diabetes Care. 41:14–31. 2018.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Marso SP, Daniels GH, Brown-Frandsen K,
Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR,
Ravn LS, et al: Liraglutide and cardiovascular outcomes in type 2
diabetes. N Engl J Med. 375:311–322. 2016.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Helmstädter J, Keppeler K, Küster L,
Münzel T, Daiber A and Steven S: Glucagon-like peptide-1 (GLP-1)
receptor agonists and their cardiovascular benefits-The role of the
GLP-1 receptor. Br J Pharmacol. 179:659–676. 2022.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Knuuti J, Wijns W, Saraste A, Capodanno D,
Barbato E, Funck-Brentano C, Prescott E, Storey R, Deaton C,
Cuisset T, et al: 2019 ESC Guidelines for the diagnosis and
management of chronic coronary syndromes: The Task Force for the
diagnosis and management of chronic coronary syndromes of the
European SOCIETY OF CARDIOlogy (ESC). Eur Heart J. 41:407–477.
2020.
|
|
121
|
American Diabetes Association. 9.
Pharmacologic approaches to glycemic treatment: Standards of
medical care in diabetes-2020. Diabetes Care. 43 (Suppl
1):S98–S110. 2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Marty VN, Farokhnia M, Munier JJ, Mulpuri
Y, Leggio L and Spigelman I: Long-acting glucagon-like peptide-1
receptor agonists suppress voluntary alcohol intake in male wistar
rats. Front Neurosci. 14(599646)2020.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Klausen MK, Thomsen M, Wortwein G and
Fink-Jensen A: The role of glucagon-like peptide 1 (GLP-1) in
addictive disorders. Br J Pharmacol. 179:625–641. 2022.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Graham DL, Erreger K, Galli A and Stanwood
GD: GLP-1 analog attenuates cocaine reward. Mol Psychiatry.
18:961–962. 2013.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Egecioglu E, Engel JA and Jerlhag E: The
glucagon-like peptide 1 analogue, exendin-4, attenuates the
rewarding properties of psychostimulant drugs in mice. PLoS One.
8(e69010)2013.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Erreger K, Davis AR, Poe AM, Greig NH,
Stanwood GD and Galli A: Exendin-4 decreases amphetamine-induced
locomotor activity. Physiol Behav. 106:574–578. 2012.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Chaves Filho AJM, Cunha NL, de Souza AG,
Soares MV, Jucá PM, de Queiroz T, Oliveira JVS, Valvassori SS,
Barichello T, Quevedo J, et al: The GLP-1 receptor agonist
liraglutide reverses mania-like alterations and memory deficits
induced by D-amphetamine and augments lithium effects in mice:
Relevance for bipolar disorder. Prog Neuropsychopharmacol Biol
Psychiatry. 99(109872)2020.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Al-Nozha MM, Arafah MR, Al-Maatouq MA,
Khalil MZ, Khan NB, Al-Marzouki K, Al-Mazrou YY, Abdullah M,
Al-Khadra A, Al-Harthi SS, et al: Hyperlipidemia in Saudi Arabia.
Saudi Med J. 29:282–287. 2008.PubMed/NCBI
|
|
129
|
Okati-Aliabad H, Ansari-Moghaddam A,
Kargar S and Jabbari N: Prevalence of obesity and overweight among
adults in the Middle East countries from 2000 to 2020: A systematic
review and meta-analysis. J Obes. 2022(8074837)2022.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Alshaikh A, Aljedai A, Alfadda A,
Alrobayan A, Bawahab A, Ouf SA, Sultan A, Alhozali A, Bawazeer M,
Sheshah E, et al: Clinical practice guideline for the management of
overweight and obesity in adults in Saudi Arabia. Int J Clin Med.
13:590–649. 2022.
|
|
131
|
World Health Organization: Saudi Arabia
health profile 2015. World Health Organization. Regional Office for
the Eastern Mediterranean, 2016.
|
|
132
|
Memish ZA, El Bcheraoui C, Tuffaha M,
Robinson M, Daoud F, Jaber S, Mikhitarian S, Al Saeedi M, AlMazroa
MA, Mokdad AH and Al Rabeeah AA: Obesity and associated
factors-Kingdom of Saudi Arabia, 2013. Prev Chronic Dis.
11(E174)2014.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Al-Omar HA, Alshehri A, Alqahtani SA,
Alabdulkarim H, Alrumaih A and Eldin MS: A systematic review of
obesity burden in Saudi Arabia: Prevalence and associated
co-morbidities. Saudi Pharm J. 32(102192)2024.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Bin Horaib G, Al-Khashan HI, Mishriky AM,
Selim MA, Alnowaiser N, Binsaeed AA, Alawad AD, Al-Asmari AK and
Alqumaizi K: Prevalence of obesity among military personnel in
Saudi Arabia and associated risk factors. Saudi Med J. 34:401–407.
2013.PubMed/NCBI
|
|
135
|
Malkin JD, Baid D, Alsukait RF, Alghaith
T, Alluhidan M, Alabdulkarim H, Altowaijri A, Almalki ZS, Herbst
CH, Finkelstein EA, et al: The economic burden of overweight and
obesity in Saudi Arabia. PLoS One. 17(e0264993)2022.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Alluhidan M, Alsukait R, Alghaith T,
Shekar M and Herbst C: Overweight and obesity in Saudi Arabia:
Consequences and solutions. World Bank Publications, Washington,
DC, 2022.
|
|
137
|
Aldubayan K and Murimi M: Compliance with
school nutrition policy in Saudi Arabia: A quantitative study. East
Mediterr Health J. 25:230–238. 2019.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Gerich J, Fonseca V and Alvarado-Ruiz R:
Monotherapy with GLP-1 receptor agonist, Lixisenatide,
significantly improves glycaemic control in type 2 diabetic
patients. In: Diabetologia. Springer, New York, NY, 2010.
|
|
139
|
Sanofi-Aventis UJB, NJ, Sanofi-Aventis US
LLC: LLC: Adlyxin (Lixisenatide)[Prescribing Information],
2016.
|
|
140
|
LP APJW, DE: AstraZeneca Pharmaceuticals
LP: Imfinzi (durvalumab) injection, for intravenous use
[prescribing information], 2017.
|
|
141
|
Derosa G, Franzetti IG, Querci F, Carbone
A, Ciccarelli L, Piccinni MN, Fogari E and Maffioli P: Exenatide
plus metformin compared with metformin alone on β-cell function in
patients with Type 2 diabetes. Diabet Med. 29:1515–1523.
2012.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Htike ZZ, Zaccardi F, Papamargaritis D,
Webb DR, Khunti K and Davies MJ: Efficacy and safety of
glucagon-like peptide-1 receptor agonists in type 2 diabetes: A
systematic review and mixed-treatment comparison analysis. Diabetes
Obes Metab. 19:524–536. 2017.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Chun E, Siojo A, Rivera D, Reyna K, Legere
H, Joseph R and Pojednic R: Weight loss and body composition after
compounded semaglutide treatment in a real world setting. Diabetes
Obes Metab. 27:1536–1543. 2025.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Kalra S: Choosing appropriate
glucagon-like peptide 1 receptor agonists: A patient-centered
approach. Diabetes Ther. 5:333–340. 2014.PubMed/NCBI View Article : Google Scholar
|
|
145
|
GlaxoSmithKline G: Tanzeum (albiglutide)
prescribing informtion, 2015.
|
|
146
|
Geiser JS, Heathman MA, Cui X, Martin J,
Loghin C, Chien JY and de la Peña A: Clinical pharmacokinetics of
dulaglutide in patients with type 2 diabetes: Analyses of data from
clinical trials. Clin Pharmacokinet. 55:625–634. 2016.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Montanya E and Sesti G: A review of
efficacy and safety data regarding the use of liraglutide, a
once-daily human glucagon-like peptide 1 analogue, in the treatment
of type 2 diabetes mellitus. Clin Ther. 31:2472–2488.
2009.PubMed/NCBI View Article : Google Scholar
|
|
148
|
O'Neil PM, Birkenfeld AL, McGowan B,
Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M
and Wilding JPH: Efficacy and safety of semaglutide compared with
liraglutide and placebo for weight loss in patients with obesity: A
randomised, double-blind, placebo and active controlled,
dose-ranging, phase 2 trial. Lancet. 392:637–649. 2018.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Onge ES, Miller SA and Motycka C:
Liraglutide (Saxenda®) as a treatment for obesity. Food Nutr Sci.
7:227–235. 2016.
|
|
150
|
Chavda VP, Ajabiya J, Teli D, Bojarska J
and Apostolopoulos V: Tirzepatide, a new era of dual-targeted
treatment for diabetes and obesity: A mini-review. Molecules.
27(4315)2022.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Cai W, Zhang R, Yao Y, Wu Q and Zhang J:
Tirzepatide as a novel effective and safe strategy for treating
obesity: A systematic review and meta-analysis of randomized
controlled trials. Front Public Health. 12(1277113)2024.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Feier CVI, Vonica RC, Faur AM, Streinu DR
and Muntean C: Assessment of thyroid carcinogenic risk and safety
profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes
mellitus and obesity: A systematic literature review. Int J Mol
Sci. 25(4346)2024.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Yang XD and Yang YY: Clinical
pharmacokinetics of semaglutide: A systematic review. Drug Des
Devel Ther. 18:2555–2570. 2024.PubMed/NCBI View Article : Google Scholar
|
